Fulda conference #9: Amygdalin (Vitamin B17/Laetrile) – advantages and risks (Dr Martin Stoppler)

FuldaMarket1

The Christmas market at Fulda. image credit: http://www.germany.travel/

Updated March 2016 – For more information on GcMAF, please join the GcMAF and GcMAF Cancer forums on Facebook – they are closed groups, so you have to wait for your membership to be confirmed.  They contain up-to-date information on sources of GcMAF, and also feedback and contributions  by people who are using GcMAF.

Dr Martin Stoppler studied medicine from 1980-86, and specialised in general medicine in 1992 and naturopathic treatments in 1996.  He has been practising in his own complementary therapy clinic since 1992.  He is a founding member of the registered society Forum of Orthomolecular Medicine.

He talks about his experience with amygdalin together with other therapies, for example, GcMAF for 2 years in combination:  “From my experience GcMAF also has an excellent effect in depressed patients. However, since the possibly existing interference must be suppressed before. I use GcMAF in acute and chronic inflammation, such as rheumatoid arthritis successfully. In addition, I inject directly into GcMAF malignant tumors and involved lymph nodes.”

Also of interest is how he has used B17 in the face of opposition from the German authorities as B17 is on the list of dangerous substances in Germany.  His house has been broken into several times by the police, he has been threatened, and his dog almost killed.  He has persisted because he has seen B17 work for his patients.

He came across as very passionate and caring for his patients, and willing to go the extra mile for his patients.

Dr med. Martin Stoppler

http://www.aprikosenkerne-gegen-krebs.de/

practice- your-doctor-in-internet.de, praxisihr-arzt-im-internet.de

********

Brief background

Dr Stoppler was inspired by a book by Phillip Day “Cancer”.

Dr Hans Nieper was the pioneer of B17 use in Germany (1928-98)

Dr Kanematsu Sugiura

In Germany, B17 is on the list of dangerous substances.

In 2006, 2009 and 5 weeks’ pre-conference, the police visited Dr Stoppler.  Went to his practice and his home and threatened to kill his dog.

He went through 1.5 years of court proceedings, Euro8,000 fine.  He gets around it by ordering the drugs on behalf of the patient.

What is B17?

B17 is not really a vitamin.  It is a substance found in 1,200 plants.

LD50 Mouse 443mg/kg – lethal dose

LD50 Rat = 405mg/kg – lethal dose

Recommended 9g to 12-15g/kg – human dose

Side-effects of B17:

Results in high concentration of beta-glucosidase.

Oral version – diarrhoea, GI symptoms, constipation.

Herxeimher’s reaction – toxins or tumour cells degrading.  Chills, shaking and fever.  Ozone first – non-activated MMS – liver detox and support.  Bicarbonate – IV C 20-42g

Why has a patient become ill?

– Activation or excess of free radicals.  Toxins e.g. aluminium and lead, UV.

Main factors

Stress, that the patient sees as negative.  Psycho-oncology

Also – teeth – deficits in micro-nutrient field.

Digestive system.

Other treatments

102mg sodium selnite

Germanium sesquioxide – works through oxygen pathway

DCA – bodyweight dependent – IV 15mg/kg of bodyweight

DMSO – IV – saline – transports B17.  Not in a glucose solution.  5ml didn’t work – nausea and vomiting.  05-1ml/250ml.

Dr Pachmann’s lab in Bayreuth – Maintrac

Use of magnetic mats and cortisol for allergies

GcMAF protocol

GcMAF – injects into tumour and ascites.

uPAR – Urokinase-type plasminogen activator receptor – 400ng

Vitamin D level – 200-300 or 400-500 if using GcMAF.

3,000 IU orally

Decristol – 10 capsules 200,000/day [this is Vitamin D in Germany]

Doesn’t use nagalase test because of fluctuations during the day

GcMAF – IV twice weekly – 400ng

B17 protocol

B17 – phasing in 3g-6-9g.  1st week Monday, Wed, Fri.  2nd week, twice weekly.  6th week – oral administration

Dr Stoppler starts with 9g.  Causes Herxheimer’s depending on patient.

Kinofsky index of 60-70 drink a lot.

4 hours of treatment – exhausting for patient.

B17 supplier in Hamburg – 3g/5ml solution

Would like more research – is there an upper limit?

400ml/kg (bei 70kg = 31.5g)

B17 is not a monotherapy

uses DMSO as a transport molecule = 0.5ml

Access to Medical Innovation Bill about to become law in UK

The Access to Medical Innovation Bill will set up a database to collect the methods and results of all medical innovations by individual doctors across England and Wales so that successes and failures can be seen and shared by other doctors, scientists and researchers.

Lord Maurice Saatchi who sits in the House of Lords and his team have been working to get a Medical Innovations Bill approved.  It’s only taken them 4 years.  The final step is for the Queen to formally sign it.

Apparently, this database will drive forward evidence-based, medical science.

Many doctors innovate today, in their clinics, trying new techniques and drugs – but if no one knows about these innovations, other doctors cannot adopt and perfect them.

Lord Saatchi was motivated to create the Bill after the death of his wife, from peritoneal cancer.  She was a novelist, a scholar and promoter of poetry, a publisher and a theatre producer.

I’d be interested to see how this Bill will be implemented.

I think this is supposed to be a step towards openness about cancer treatments, in particular, non-allopathic treatments.  And hopefully it will encourage doctors who have tried non-allopathic treatments to share their successes.

Whether this will protect them from the long-arm of the law who is still on the side of allopathic medicine, I have serious doubts.  Why share if all you’re going to get is a jail sentence for using B17?

I am still not clear how this will work.  Is it just a database of information?  Is it compulsory?  If it is not made compulsory, why would doctors bother with the red tape of sending in their results?  Who is going to enforce this Bill and make sure doctors toe the line?

There’s also the problem that for many non-allopathic doctors who treat cancer, there is no one set protocol.  Let me clarify:  an oncologist would have a set protocol for treating cancer, which is determined by trials and statistics.  Every oncologist would follow the same set protocol.  For a non-allopathic doctor, treatments vary according to the patient.  So there is one-size-fits-all approach.  How then to replicate any success if it’s dependent on so many variables?

And there’s the issue of the Cancer Act 1939 which persecutes any treatment (mainly non-allopathic is my understanding) that purports to be a cancer cure.  I can understand why it was put in place because cancer patients are vulnerable and desperate for cures, and there are a lot of quacks and con-men out there.

I cannot see non-allopathic doctors risking their livelihood by sending in their results.  Also, all the non-allopathic doctors I’ve come across are far too busy trying to save the lives of their patients to bother with more red tape.  And justifiably so.  I would rather a doctor be focused on me than paperwork.

What I’d like to see is the government supporting innovation, the way they do in Germany where off-label treatments are permitted, and incredible success stories exist, and doctors and clinics are willing to take risks because they are NOT persecuted for innovation.  This Medical Innovations Bill doesn’t go far enough and may in effect open a can of worms by exposing well-meaning doctors who are stepping off-piste to persecution.